Dr. Reddys Laboratories is currently trading at Rs 3574.00, down by 33.80 points or 0.94% from its previous closing of Rs 3607.80 on the BSE.
The scrip opened at Rs. 3587.00 and has touched a high and low of Rs. 3587.00 and Rs. 3562.20 respectively. So far 2695 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3633.00 and Rs. 3475.40 respectively. The current market cap of the company is Rs. 60940.51 crore.
The promoters holding in the company stood at 25.58% while Institutions and Non-Institutions held 42.02% and 32.40% respectively.
Dr. Reddy’s Laboratories is recalling 9,330 bottles of Sirolimus tablets in the US due to presence of impurities. The tablets were manufactured by pharma major at its Visakhapatnam plant. Sirolimus tablets are indicated for the prevention of organ rejection in patients aged 13 years or older receiving renal transplants.
According to United States Food and Drug Administration (USFDA), the pharma major’s US arm - Dr. Reddy’s Laboratories Inc is recalling 9,330 bottles of Sirolimus tablets, 1 mg on account of failed impurities. The reason for recall is ‘failed impurities/degradation: out of specification result for impurity secorapamycin’.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1875.55 |
| Dr. Reddys Lab | 1285.40 |
| Cipla | 1339.50 |
| Zydus Lifesciences | 939.60 |
| Lupin | 2255.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: